- Home
- Middle East And Africa Primary Angle Closure Glaucoma Market

Middle East and Africa Primary Angle-Closure Glaucoma Market - Industry Trends and Forecast to 2028
- Published Date: September, 2022 | Report ID: CLS-264 | No of pages: 80 | Format:
Middle East and Africa primary angle-closure glaucoma market is projected to register a CAGR of 5.2% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028
Market Segmentation:
Middle East and Africa Primary Angle-Closure Glaucoma Market, By Disease Type (Acute Angle-Closure Glaucoma and Chronic Angle-Closure Glaucoma), Type (Diagnosis and Treatment), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (South Africa, Egypt, Saudi Arabia, Israel, UAE, Kuwait, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Some of the major factors contributing to the growth of the Middle East and Africa primary angle-closure glaucoma market are:
Increasing prevalence of angle-closure glaucoma
Rise in women population
Growing in geriatric population
Market Players:
The key market players for Middle East and Africa primary angle-closure glaucoma market are listed below:
Johnson & Johnson Vision Care, Inc. (a subsidiary of Johnson & Johnson Services Inc.)
Bausch & Lomb (a subsidiary of Bausch Health)
Alcon Inc
NIDEK CO., LTD
Allergan (a subsidiary of AbbVie Inc.)
BVI
Oertli Instrumente AG
Reichert Inc
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 1.1 OBJECTIVES OF THE STUDY 1.2 MARKET DEFINITION 1.3 OVERVIEW OF MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET 1.4 LIMITATIONS 1.5 MARKETS COVERED 2 MARKET SEGMENTATION 2.1 MARKETS COVERED 2.2 GEOGRAPHICAL SCOPE 2.3 YEARS CONSIDERED FOR THE STUDY 2.4 CURRENCY AND PRICING 2.5 DBMR TRIPOD DATA VALIDATION MODEL 2.6 MULTIVARIATE MODELLING 2.7 TYPE LIFELINE CURVE 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 2.9 DBMR MARKET POSITION GRID 2.10 MARKET END USER COVERAGE GRID 2.11 VENDOR SHARE ANALYSIS 2.12 SECONDARY SOURCES 2.13 ASSUMPTIONS 3 EXECUTIVE SUMMARY 4 EPIDEMIOLOGY 5 REGULATORY FRAMEWORK 6 PIPELINE ANALYSIS 7 MARKET OVERVIEW 7.1 DRIVERS 7.1.1 INCREASING PREVALENCE OF ANGLE-CLOSURE GLAUCOMA 7.1.2 INCREASING WOMEN POPULATION 7.1.3 RISE IN GERIATRIC POPULATION 7.1.4 ADVANCEMENTS IN SURGICAL TREATMENT OF THE DISEASE 7.1.5 INCREASED ECONOMIC BURDEN 7.2 RESTRAINTS 7.2.1 HIGH SURGICAL COSTS OF PACG 7.2.2 INADEQUATE REIMBURSEMENT SCENARIO 7.2.3 DELAYED AND MISDIAGNOSIS OF PACG 7.3 OPPORTUNITIES 7.3.1 INCREASING GOVERNMENT INITIATIVES TOWARDS GLAUCOMA 7.3.2 RECENT APPROVAL BY GOVERNING BODIES 7.3.3 INCREASING INCIDENCES IN EMERGING MARKET 7.3.4 RAPID TRANSITION FROM PACG MEDICATION TO SURGERIES 7.4 CHALLENGES 7.4.1 RISKS ASSOCIATED WITH SURGICAL PROCEDURES 7.4.2 LACK OF SKILLED PROFESSIONALS WITH ADEQUATE KNOWLEDGE 7.4.3 LIMITED ACCESS TO TREATMENT 8 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET 8.1 IMPACT ON PRICE 8.2 IMPACT ON DEMAND 8.3 IMPACT ON SUPPLY CHAIN 8.4 STRATEGIC DECISION BY MANUFACTURERS 8.5 CONCLUSION 9 MIDDLE EAST AND AFRICA PRIMARY ANGLE CLOSURE GLAUCOMA MARKET, BY DISEASE TYPE 9.1 OVERVIEW 9.2 ACUTE ANGLE-CLOSURE GLAUCOMA MARKET 9.3 CHRONIC ANGLE-CLOSURE GLAUCOMA MARKET 10 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY TYPE 10.1 OVERVIEW 10.2 DIAGNOSIS 10.2.1 PRIMARY TEST 10.2.1.1 GONIOSCOPY EXAMINATION 10.2.1.2 SLIT-LAMP EXAMINATION 10.2.1.3 AUTOMATIC STATIC PERIMETRY 10.2.2 SECONDARY TEST 10.2.2.1 ULTRASOUND BIOMICROSCOPY 10.2.2.2 ANTERIOR SEGMENT OPTICAL COHERENCE TOMOGRAPHY (OCT) 10.2.2.3 RETINAL OCT 10.2.2.4 FUNDOSCOPY 10.2.2.5 OTHERS 10.3 TREATMENT 10.3.1 SURGICAL IRIDECTOMY 10.3.2 TRABECULECTOMY 10.3.3 MICRO INVASIVE GLAUCOMA TECHNIQUE (MIGS) 10.3.4 GONIOTOMY 10.3.5 OTHERS 11 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY END USER 11.1 OVERVIEW 11.2 HOSPITALS 11.3 AMBULATORY SURGICAL CENTERS 11.4 SPECIALTY CLINICS 11.5 OTHERS 12 MIDDLE EAST AND AFRICA PROSTATE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 12.1 OVERVIEW 12.2 DIRECT TENDER 12.3 RETAIL SALES 12.4 OTHERS 13 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET, BY GEOGRAPHY 13.1 MIDDLE EAST AND AFRICA 13.1.1 SOUTH AFRICA 13.1.2 EGYPT 13.1.3 SAUDI ARABIA 13.1.4 ISRAEL 13.1.5 UAE 13.1.6 KUWAIT 13.1.7 REST OF MIDDLE EAST AND AFRICA 14 MIDDLE EAST AND AFRICA PRIMARY ANGLE-CLOSURE GLAUCOMA MARKET: COMPANY LANDSCAPE 14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 15 SWOT 16 COMPANY PROFILES 16.1 JOHNSON & JOHNSON VISION CARE, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 16.1.1 COMPANY SNAPSHOT 16.1.2 REVENUE ANALYSIS 16.1.3 COMPANY SHARE ANALYSIS 16.1.4 PRODUCT PORTFOLIO 16.1.5 RECENT DEVELOPMENTS 16.2 BAUSCH & LOMB INCORPORATED (A SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.) 16.2.1 COMPANY SNAPSHOT 16.2.2 REVENUE ANALYSIS 16.2.3 COMPANY SHARE ANALYSIS 16.2.4 PRODUCT PORTFOLIO 16.2.5 RECENT DEVELOPMENTS 16.3 ALCON INC. 16.3.1 COMPANY SNAPSHOT 16.3.2 REVENUE ANALYSIS 16.3.3 COMPANY SHARE ANALYSIS 16.3.4 PRODUCT PORTFOLIO 16.3.5 RECENT DEVELOPMENTS 16.4 ZEISS INTERNATIONAL 16.4.1 COMPANY SNAPSHOT 16.4.2 REVENUE ANALYSIS 16.4.3 COMPANY SHARE ANALYSIS 16.4.4 PRODUCT PORTFOLIO 16.4.5 RECENT DEVELOPMENTS 16.5 NOVA EYE MEDICAL LIMITED 16.5.1 COMPANY SNAPSHOT 16.5.2 REVENUE ANALYSIS 16.5.3 PRODUCT PORTFOLIO 16.5.4 RECENT DEVELOPMENTS 16.6 NIDEK CO., LTD 16.6.1 COMPANY SNAPSHOT 16.6.2 PRODUCT PORTFOLIO 16.6.3 RECENT DEVELOPMENTS 16.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.) 16.7.1 COMPANY SNAPSHOT 16.7.2 REVENUE ANALYSIS 16.7.3 PRODUCT PORTFOLIO 16.7.4 RECENT DEVELOPMENT 16.8 APPASAMY ASSOCIATES 16.8.1 COMPANY SNAPSHOT 16.8.2 PRODUCT PORTFOLIO 16.8.3 RECENT DEVELOPMENT 16.9 AUROLAB 16.9.1 COMPANY SNAPSHOT 16.9.2 PRODUCT PORTFOLIO 16.9.3 RECENT DEVELOPMENT 16.10 BVI 16.10.1 COMPANY SNAPSHOT 16.10.2 PRODUCT PORTFOLIO 16.10.3 RECENT DEVELOPMENTS 16.11 LIGHTMED 16.11.1 COMPANY SNAPSHOT 16.11.2 PRODUCT PORTFOLIO 16.11.3 RECENT DEVELOPMENTS 16.12 LUNEAU TECHNOLOGY USA 16.12.1 COMPANY SNAPSHOT 16.12.2 PRODUCT PORTFOLIO 16.12.3 RECENT DEVELOPMENT 16.13 MEDISONIC EQUIPMENTS PVT. LTD. 16.13.1 COMPANY SNAPSHOT 16.13.2 PRODUCT PORTFOLIO 16.13.3 RECENT DEVELOPMENT 16.14 MICROSURGICAL TECHNOLOGY 16.14.1 COMPANY SNAPSHOT 16.14.2 PRODUCT PORTFOLIO 16.14.3 RECENT DEVELOPMENTS 16.15 NEW VISION 16.15.1 COMPANY SNAPSHOT 16.15.2 PRODUCT PORTFOLIO 16.15.3 RECENT DEVELOPMENTS 16.16 NEW WORLD MEDICAL, INC. 16.16.1 COMPANY SNAPSHOT 16.16.2 PRODUCT PORTFOLIO 16.16.3 RECENT DEVELOPMENTS 16.17 OERTLI INSTRUMENTE AG 16.17.1 COMPANY SNAPSHOT 16.17.2 PRODUCT PORTFOLIO 16.17.3 RECENT DEVELOPMENTS 16.18 OMNI LENS 16.18.1 COMPANY SNAPSHOT 16.18.2 PRODUCT PORTFOLIO 16.18.3 RECENT DEVELOPMENT 16.19 REICHERT, INC. (A BUSINESS UNIT OF AMETEK.INC.) 16.19.1 COMPANY SNAPSHOT 16.19.2 REVENUE ANALYSIS 16.19.3 PRODUCT PORTFOLIO 16.19.4 RECENT DEVELOPMENTS 16.20 SIGHT SCIENCES, INC. 16.20.1 COMPANY SNAPSHOT 16.20.2 PRODUCT PORTFOLIO 16.20.3 RECENT DEVELOPMENTS 17 QUESTIONNAIRE 18 RELATED REPORTSSegmentation
Short Description Middle East and Africa Primary Angle-Closure Glaucoma Market, By Disease Type (Acute Angle-Closure Glaucoma and Chronic Angle-Closure Glaucoma), Type (Diagnosis and Treatment), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (South Africa, Egypt, Saudi Arabia, Israel, UAE, Kuwait, Rest of Middle East and Africa) Industry Trends and Forecast to 2028 Market Definition: Glaucoma is a group of eye conditions that damage the optic nerve and the proper functioning of the optic nerve is necessary for good vision. This damage is often caused by abnormally high pressure in the eye. The primary angle-closure (PAC) is defined as appositional or synechial closure of the anterior chamber angle which can lead to aqueous outflow obstruction and raised IOP in the absence of glaucomatous optic neuropathy. Market Segmentation: The primary angle-closure glaucoma market is segmented on the basis of the disease type, type, end user and distribution channel. On the basis of disease type, the primary angle-closure glaucoma market is segmented into acute angle-closure glaucoma and chronic angle-closure glaucoma On the basis of type, the primary angle-closure glaucoma market is segmented into diagnosis and treatment On the basis of end user, the primary angle-closure glaucoma market is segmented into hospitals, specialty clinics, ambulatory surgical centers and others On the basis of distribution channel, the primary angle-closure glaucoma market is segmented into direct tender, retail sales and others Market Players: The key market players for Middle East and Africa primary angle-closure glaucoma market are listed below: Johnson & Johnson Vision Care, Inc. (a subsidiary of Johnson & Johnson Services Inc.) Bausch & Lomb (a subsidiary of Bausch Health) Alcon Inc NIDEK CO., LTD Allergan (a subsidiary of AbbVie Inc.) BVI Oertli Instrumente AG Reichert IncMethodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.